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ABSTRACT
Background. Clinical behavior of non-muscle-invasive bladder
cancer (NMIBC) is largely unpredictable, and even patients
treated according to European Association of Urology recom-
mendations have a heterogeneous prognosis. High-grade T1
(HGT1) bladder cancer is the highest-risk subtype of NMIBC,
with an almost 40% rate of recurrence and 20% of progres-
sion at 5 years. Nomograms predicting risk of recurrence, pro-
gression, and cancer-specific survival (CSS) are not available
specifically within HGT1 bladder cancer, and the identification
of robust prognostic biomarkers to better guide therapeutic
strategies in this subgroup of patients is of paramount impor-
tance. Strategies to identify putative biomarkers in liquid biop-
sies from blood and urine collected from patients with bladder
cancer have been intensively studied in the last few years.
Subjects, Materials, and Methods. We here report the final
analysis of a single-center prospective study aimed to investigate
the impact of circulating tumor cells (CTCs) on CSS and overall
survival (OS) in 102 patients with HGT1 bladder cancer, in a
median follow-up of 63months.
Results. We here demonstrate that the presence of even
a single CTC is predictive of shorter CSS and OS, as
compared with the standard predictive variables. Points
of attention in this multivariable analysis are the long-
term follow-up and the adequate number of outcome
events.
Conclusion. The accurate risk stratification provided by
CTCs might be essential for determining the best surveil-
lance strategy for patients after diagnosis. A closer
follow-up, an early radical surgery, or even a systemic
treatment might be recommended in patients with
super-high-risk non-muscle-invasive bladder cancer. The
Oncologist 2019;24:1–5
Implications for Practice: Circulating tumor cells identify patients with super-high-risk non-muscle-invasive bladder cancer
who require closer monitoring for local recurrence and/or progression of disease. This super-high-risk subgroup of patients
might also require more aggressive treatment interventions, which should be evaluated in large prospective cohorts.
INTRODUCTION
The vast majority of bladder cancers are classified as non-
muscle-invasive bladder cancer (NMIBC) at diagnosis. NMIBC
are heterogeneous cancers, at the biological and clinical level,
with a large degree of variation in clinical presentation, course,
and outcomes. T1 tumors (lesions that extend to the lamina
propria layer of the bladder) account for approximately 20% of
all NMIBC and have the highest rate of recurrence, progression,
and cancer-specific mortality. High-grade T1 (HGT1) bladder
cancer is the highest-risk subtype of NMIBC, with an almost
40% rate of recurrence and 20% of progression at 5 years,
despite primary intravesical therapy with Bacillus Calmette-
Guérin (BCG) [1]. The pathophysiology behind the aggressive
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nature of HGT1 bladder cancer has not yet been fully eluci-
dated. It has been hypothesized that the poor clinical outcome
of some patients is either due to the understaging of T2 lesions
or to an inherent biological aggressiveness of the tumor [2].
Clinical and pathological features have been shown to be major
determinants of long-term outcomes. In the last decade, two
prognostic models, derived from two large European research
consortia, the European Organisation for Research and Treat-
ment of Cancer and Spanish Urological Club for Oncological
Treatment, have been proposed to estimate the risk of re-
currence and progression to muscle-invasive disease. Both
models have been proposed for use in the broader NMIBC
population and calculate the risk profile on the basis of tumor
grade and stage, prior recurrences, tumor size, multifocality,
and the presence of carcinoma in situ (CIS) [3]. Nomograms
predicting risk of recurrence, progression, and cancer-specific
survival (CSS) are not available specifically within HGT1 bladder
cancer, and current models have shown limited predictive value
in this high-risk subtype of bladder cancer [4]. An accurate pre-
diction of progression is critically important in the management
of NMIBC. Indeed, owing to limitations in risk stratification,
patients with T1 bladder cancer are at risk of being either
undertreated, with persistent use of BCG despite recurrence, or
overtreated with avoidable early cystectomy. The identification
of robust prognostic biomarkers could better guide therapeutic
strategies for patients with high-risk non-muscle-invasive blad-
der cancer, which remains a very challenging disease. Over the
past decades, the knowledge of the molecular background of
bladder cancer has dramatically improved and deregulation
of tumor suppressor genes, oncogenes, cell cycle regulators,
growth factors and receptors, and cell adhesion molecules
has been recognized. So far, molecular markers are rarely dis-
criminatory enough for clinical use as individual markers,
although the combination with clinical data may improve
their prognostic power [5]. There is general agreement that
by adding biomarkers that reflect the biologic behavior of
HGT1 bladder cancer to established parameters in nomo-
grams, significant improvements in risk stratification could be
achieved. Strategies to identify putative biomarkers in liquid
biopsies from blood and urine collected from patients with
bladder cancer are being developed to monitor subclinical sys-
temic disease and to identify candidate targets for therapeutic
intervention [6]. Circulating tumor cells (CTCs), in particular,
are regarded as surrogate for early dissemination of disease
and have been qualified as accurate prognostic biomarkers in
different cancer types, including bladder cancer [7]. We have
previously demonstrated that, in a cohort of 102 patients
with HRT1 bladder cancer, the presence of CTCs (detectable in
20% of patients) predicted both decreased time to first recur-
rence and time to progression (median follow-up 24.3 months),
thus identifying a subgroup of patients with super-high-risk
CTC-positive non-muscle-invasive bladder cancer [8]. We here
report the updated outcome analysis and mature results for
cancer-specific survival and overall survival (OS) in a median
follow-up of 63 months.
SUBJECTS, MATERIALS, AND METHODS
Weconductedaprospective single-center analysis in 102patients
with pathologically confirmed high-risk T1G3 transitional cell
tumor, treated at our institution between September 2010 and
January 2013, according to standard international guidelines:
transurethral resection of bladder (TURB) followed by re-TURB
and BCG induction plus maintenance 1–3 years. Patients
follow-up was planned with a cystoscopy and urinary cytology
every 3 months and a contrast-enhanced computed tomogra-
phy scan every 12 months. CTCs were isolated before the first
TURB from 7.5 mL of blood collected into evacuated blood
draw tubes through CellSearch system (Menarini Silicon Bio-
systems, Castel Maggiore, Bologna, Italy), according to manu-
facturer’s instructions [9]. We had previously demonstrated
that the presence of even a single CTC is significantly associ-
ated with shorter time to first recurrence (TFR) and time to
progression (TTP) in a median follow-up of 24 months, attes-
ting for the first time the powerful prediction of disease recur-
rence and progression provided by CTCs in patients with
high-grade T1 bladder cancer [8]. Updated outcome analysis
and mature CSS and OS results are reported here in a median
Table 1. Main baseline characteristics of the study
population (Number: 102)
Characteristics Patients, n (%)
Age, years
Median (range) 74 (42–90)
Gender
Male 95 (93.1)
Female 7 (6.9)
CTC
No 82 (80.4)
Yes 20 (19.6)
CIS
No 81 (79.4)
Yes 21 (20.6)
Multifocal
No 24 (23.5)
Yes 78 (76.5)
LVI
No 86 (84.3)
Yes 16 (15.7)
Tumor size, cm
<1 25 (24.5)
1–3 51 (50.0)
>3 26 (25.5)
Adj BCG after Re-TURB 102 (100)
First recurrence 64 (62.7)
Second recurrence 51 (50)
Progression to T2 (MIBC) 32 (31.4)
Progression to M1 (MBC) 17 (16.7)
Death
Cancer specific 17 (16.7)
Other cause 15 (14.7)
Abbreviations: Adj BCG, adjuvant Bacillus Calmette-Guérin; CIS, car-
cinoma in situ; CTC, circulating tumor cells; LVI, lymphovascular
invasion; MBC, metastatic bladder cancer; MIBC, muscle-invasive
bladder cancer; re-TURB, repeat transurethral resection of bladder.
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follow-up of 63 months. Descriptive statistics were used
to summarize pertinent study information. The association
between variables was tested by the Pearson chi-square test
or the Fisher’s exact test. Survival was calculated by the
Kaplan-Meier product-limit method. The log-rank test was
used to assess differences between subgroups. Univariate
Cox proportional hazards models were built using gender, age,
presence of CTC, CIS, lymph vascular invasion, multifocal, tumor
size as covariates for TFR, metastasis-free survival (MFS), TTP,
time to second recurrence (TSR), OS, and CSS. Significance was
defined at the p ≤ .05 level. Amultivariate Cox proportional haz-
ards model was also developed using stepwise regression (for-
ward selection) by selecting those predictive variables that
were significant upon univariate analysis; enter limit and
remove limit were p = .05 and p = .10, respectively. Statisti-
cal analysis was performed with SPSS software (SPSS ver-
sion 21.0; SPSS Inc., Chicago, IL).
RESULTS
In the study population, CTCs were found in 20/102 (20%)
patients. Median CTCs number was 1 (range 1–50). Median
follow-up of this final analysis was 63 months (range 11–90).
Patients that were still alive at the end of the study were
followed for at least 61 months. General characteristics of
the study population are described in Table 1. Kaplan-Meier
analysis revealed a correlation between CTCs and long-term
survival. The final analysis substantiated results obtained at
24 months of median follow-up showing a statistically signif-
icant p value for TFR (p < .0001), TSR (p < .0001), and TTP
(p < .0001). The presence of at least one CTC was also found
to be clearly associated with shorter MFS (p < .0001), CSS
(p < .0001), and OS (p = .0001; Fig. 1). Multivariable analysis
confirmed that CTCs, as compared with the standard predic-
tive variables (multifocality, CIS, lymph vascular invasion),
have the strongest negative prognostic impact for all the
outcomes analyzed (TFR hazard ratio [HR] 4.26 [2.13–8.52]
p < .0001; TSR HR 3.53 [1.81–6.87] p < .0001; TTP 7.32
[3.29–16.27] p < .0001; MFS HR 18.75 [6.01–58.47] p < .0001;
CSS HR 13.68 [4.27–43.8] p < .0001; OS HR 3.68 [1.81–7.51]
p < .0001). Points of attention in this multivariable analysis
are the long-term follow-up and the adequate number of out-
come events [10]. Multivariable analysis is detailed in Table 2.
Number of events per variable in CTC-positive versus CTC-
negative subgroups are shown in Table 3.
DISCUSSION
Since the introduction of intravesical BCG therapy almost
40 years ago, the medical management of NMIBC has
remained static. Multiple novel agents to be used in combi-
nation with BCG, as an alternative to BCG or after BCG
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Figure 1. Kaplan-Meier curves. (A): TFR. (B): TSR. (C): TTP. (D): CSS. (E): MFS. (F): OS.
Abbreviations: CTC, circulating tumor cells; CSS, cancer-specific survival; MFS, metastasis-free survival; OS, overall survival; TFR,
time to first recurrence; TSR, time to second recurrence; TTP, time to progression.
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failure, are being explored and show great promise [11].
Current models fail to accurately identify patients with
NMIBC who are at the highest risk of progression to muscle-
invasive and/or metastatic disease, despite adjuvant treat-
ment with BCG immunotherapy. Furthermore, we still lack
biomarkers for the assessment of the biologic potential and
clinical behavior of this complex disease, which could allow
for a decisive improvement of patients’ outcomes [12]. The
results from this study suggest that in a subgroup of patients
with HRT1 bladder cancer, CTCs might indicate a subclinical
systemic disease. The accurate risk stratification provided by
CTCs analysis might be used, in the near future, for deter-
mining the best surveillance strategy for patients after diag-
nosis. A closer follow-up, an early radical surgery, or even a
systemic treatment might be recommended in this super-
high-risk CTC-positive non-muscle-invasive bladder cancer
subgroup. The term “liquid biopsy” refers to a noninvasive
test that can identify markers of various types of cancer in
fluid samples such as blood or urine. Among the different
approaches for liquid biopsy, the analysis of CTCs is cer-
tainly the oldest technique. The CellSearch platform for the
isolation of circulating tumor cells from peripheral blood
has been on the market for 12 years; it was originally
cleared by the U.S. Food and Drug Administration in 2004
for in vitro diagnostic use in patients with metastatic breast
cancer and subsequently showed clinical relevance in many
other cancer types [7]. The study reported here was started
early in 2010, when the first patients with HRT1 bladder
cancer was enrolled. We here report the final analysis of
results after a median follow-up of 63 months. This reveals
that the presence of even a single CTC in peripheral blood
of HGT1 patients is clearly associated with shorter overall
and cancer-specific survival. We are aware that, since this
study was conceived and then conducted, the knowledge of
the molecular background of NMIBC has significantly evolved
and that since then a wide variety of isolation and detection
methods have been developed to enrich and enumerate
CTCs. Besides, in the last few years, it became clear that spe-
cific molecular differences exist between high- and low-grade
NMIBC and that the genetic alterations found in high-grade
NMIBC more closely resemble those present in MIBC [13].
Recent studies have demonstrated that cancer-associated
mutations and other DNA alterations can be detected in
body fluids, thus providing impetus to the technological
advances for circulating tumor DNA analysis in blood and
urine from patients with bladder cancer [14]. Given the
increasingly complex mutational landscape and intratumor
heterogeneity of the disease, it is unlikely that a single bio-
marker will able to fill the gap in the discrimination of
patients at the highest risk of progression to muscle-invasive
disease and/or metastatic dissemination. Current risk stratifi-
cation models do not include any molecular markers or any
analyte from body fluids. It will be important to determine
whether the molecular knowledge of HRT1 bladder cancer
can improve the management of patients, particularly those
at very high risk of progression. Combining new prognostic
factors into risk-prediction nomograms with validation in
prospective cohorts would be of undeniable value.
CONCLUSION
The presence of even a single CTC in peripheral blood of
patients with HRT1 bladder cancer identifies patients with
super-high-risk non-muscle-invasive bladder cancer at a very
high risk of local recurrence and/or progression of disease.
This updated outcome analysis reports mature results for
cancer-specific survival and overall survival in a median
follow-up of 63 months, demonstrating that patients with
CTC-positive HRT1 bladder cancer have shorter metastasis-
Table 2. Multivariate Cox proportional hazards model
Outcome HR 95% CI p value
TFR
CTC (yes vs. no) 4.26 2.13–8.52 <.0001
Multifocality (yes vs. no) 2.96 1.31–6.85 .009
LVI (yes vs. no) 2.17 1.09–4.30 .03
TSR
CTC (yes vs. no) 3.53 1.81–6.87 <.0001
Multifocality (yes vs. no) 3.48 1.21–9.96 .02
LVI (yes vs. no) 2.42 1.25–4.70 .009
TTP
CTC (yes vs. no) 7.32 3.29–16.27 <.0001
CIS (yes vs. no) 2.81 1.27–6.19 .01
Multifocality (yes vs. no) N/A N/A <.001
MFS
CTC (yes vs. no) 18.75 6.01–58.47 <.0001
Age 1.08 1.01–1.16 .03
OS
CTC (yes vs. no) 3.68 1.81–7.51 <.0001
Age 1.07 1.02–1.23 .008
CSS
CTC (yes vs. no) 13.68 4.27–43.80 <.0001
Sex (female vs. male) 3.20 1.03–9.90 .04
Abbreviations: CI, confidence interval; CIS, carcinoma in situ; CSS,
cancer-specific survival; CTC, circulating tumor cells; HR, hazard
ratio; LVI, lymphovascular invasion; MFS, metastasis-free survival;
N/A, not applicable; OS, overall survival; TFR, time to first recur-
rence; TSR, time to second recurrence; TTP, time to progression.
Table 3. Number of events per variable in CTC-positive
versus CTC-negative subgroups
Outcome
CTC negative,
n (%)
CTC positive,
n (%)
p valuen = 82 n = 20
TTP 14 (17.1) 18 (90.0) <.0001
MFS 4 (4.9) 13 (65.0) <.0001
TFR 44 (53.7) 20 (100) <.0001
TSR 33 (40.2) 18 (90.0) <.0001
Death <.0001
Cancer specific 4 (4.9) 13 (65.0)
Other cause 15 (18.3) 0 (0)
Abbreviations: CTC, circulating tumor cells; MFS, metastasis-free
survival; TFR, time to first recurrence; TSR, time to second recur-
rence; TTP, time to progression.
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free survival, cancer-specific survival, and overall survival,
thus connoting CTCs as a reliable tool to improve the accu-
racy of current risk stratification models.
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